IL-6 Levels Influence 3-Month All-Cause Mortality in Frail Hospitalized Older Patients.
IL6
MPI
albumin
elderly
frailty
in-hospital mortality
Journal
Aging and disease
ISSN: 2152-5250
Titre abrégé: Aging Dis
Pays: United States
ID NLM: 101540533
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
08
06
2020
accepted:
13
07
2020
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
epublish
Résumé
The multidimensional prognostic index (MPI) is a sensitive and specific prognosis estimation tool that accurately predicts all-cause mortality in frail older patients. It has been validated to assess the risk of 1-month to 2-year mortality in frail older patients during hospitalization and after hospital discharge. However, whether the MPI is a valid prognostic tool for follow-up periods of different lengths remains to be validated. To this end, we followed up 80 hospitalized patients (female=37, male 43) at least 75 years of age (mean age=82.6±4.4, range=75-94 years) to assess the 3-month all-cause mortality (mean follow-up=61.0 ± 31.7 months [range 4-90 days]). Accordingly, patients were subdivided into low (MPI-1, score 0-0.33), moderate (MPI-2, score 0.34-0.66) and high (MPI-3, score 0.67-1) mortality risk classes. Moreover, baseline biochemical, inflammatory and metabolic parameters, as well as anamnestic and clinical characteristics, were obtained. Although the MPI-3 score was significantly associated with 3-month all-cause mortality in univariate analysis (HR=5.79, 95%CI=1.77-18.92, p=0.004), a multivariate model indicated that only low albumin (HR=0.33, 95%CI=0.16-0.68, p=0.003) and high IL6 (HR=1.01, 95%CI=1.00-1.02, p=0.010) levels were significantly associated with 3-month all-cause mortality. In conclusion, we suggest that measurement of IL6 as well as albumin, rather than the MPI score, may help in providing tailored therapeutic interventions to decrease short term mortality in older hospitalized individuals.
Identifiants
pubmed: 33815869
doi: 10.14336/AD.2020.0713
pii: ad-12-2-353
pmc: PMC7990358
doi:
Types de publication
Journal Article
Langues
eng
Pagination
353-359Informations de copyright
copyright: © 2021 Rizza et al.
Déclaration de conflit d'intérêts
Declaration of Competing Interests All authors declare no conflicts of interest.
Références
Age Ageing. 2016 Jan;45(1):90-6
pubmed: 26764398
J Gerontol A Biol Sci Med Sci. 2004 Mar;59(3):242-8
pubmed: 15031308
Arch Gerontol Geriatr. 2017 Nov;73:257-262
pubmed: 28866452
Am J Med. 2007 May;120(5):455-60
pubmed: 17466658
J Gerontol. 1988 Jan;43(1):M18-20
pubmed: 3335748
J Gerontol A Biol Sci Med Sci. 2009 Apr;64(4):499-502
pubmed: 19251912
Am J Clin Nutr. 2014 Apr;99(4):899-910
pubmed: 24477043
Popul Health Manag. 2010 Aug;13(4):219-25
pubmed: 20735247
J Gerontol A Biol Sci Med Sci. 2009 Aug;64(8):880-7
pubmed: 19349589
Ageing Res Rev. 2020 Jul;60:101047
pubmed: 32171786
Lancet Neurol. 2020 Mar;19(3):271-278
pubmed: 31958406
J Alzheimers Dis. 2009;18(1):191-9
pubmed: 19584441
JAMA. 2012 Jan 11;307(2):199-200
pubmed: 22235093
Circ Heart Fail. 2010 Jan;3(1):14-20
pubmed: 19850698
Rejuvenation Res. 2008 Feb;11(1):151-61
pubmed: 18173367
Nutrients. 2019 Jan 22;11(2):
pubmed: 30678180
J Am Geriatr Soc. 1993 Feb;41(2):176-81
pubmed: 8426042
Ageing Res Rev. 2016 Nov;31:1-8
pubmed: 27592340
Lancet Diabetes Endocrinol. 2018 Sep;6(9):743-752
pubmed: 30017798
Arterioscler Thromb Vasc Biol. 2020 Feb;40(2):473-482
pubmed: 31852221
J Am Geriatr Soc. 2009 Oct;57(10):1757-66
pubmed: 19694869
Proc Natl Acad Sci U S A. 1990 Dec;87(23):9383-7
pubmed: 2123555
Ageing Res Rev. 2018 Nov;47:214-277
pubmed: 30071357
Aging Cell. 2013 Jun;12(3):459-66
pubmed: 23496093